Compare Core Scientific Inc (CORZ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Pfizer Inc — how do they compare? Core Scientific Inc trades at $15.4 (market cap $5.12B), while Pfizer Inc trades at $27.81 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 31.2× Core Scientific Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Pfizer Inc for 158 Days on average.
| CORZ | PFE | |
|---|---|---|
Market Cap | $5.12B | $159.59B |
Volume | 9,296,664 | 30,937,010 |
Sector | Technology | Health |
52-Week High | $29.16 | $29.02 |
52-Week Low | $13.57 | $23.67 |
Typical Hold Time | 20 Days | 158 Days |
Enterprise Value | $7.65B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.94, down 4.44% today amid bearish technical signals. The stock shows weak fundamentals with a -324.9% net income margin and negative earnings misses in recent quarters. However, analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.46 consensus price target. Recent executive appointments and AI data center expansion plans provide growth catalysts despite current profitability challenges.
The outlook balances strong analyst conviction against fundamental weakness. While the AI infrastructure pivot offers long-term potential, investors face significant execution risks and negative cash flow. The stock trades near support levels with technical indicators suggesting caution, requiring careful monitoring of revenue growth and margin improvement for sustained recovery.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
